410,00 € – 414,00 €
This antibody reacts with the CD45RO antigen, which is present at low density early in the T-lymphocyte maturation cycle. Upon activation by phytohemagglutinin (PHA) or alloantigen, naive T lymphocytes first acquire CD45RO and then lose CD45RA. When these activated T lymphocytes are rechallenged, the cells that exhibit a secondary response are primarily CD45RO +, leading to the concept that CD45RO + cells are a primed population of memory T lymphocytes.
In peripheral blood, the CD45RO antigen is present on approximately 40% of resting peripheral blood T lymphocytes, including the CD4 + and CD8 + subpopulations, as well as on most thymocytes and activated T lymphocytes. It is also expressed on monocytes, macrophages, and granulocytes.
Conjugated | |
---|---|
Size | |
Clone | |
Gene ID | |
Format | |
Species Reactivity | |
Isotype | |
Tested Applications | |
Clonality | |
Regulatory Status | |
UniProt | |
Mw | |
Storage | Store in the dark at 2-8°C. |
Other names | Restricted T200. |
Buffer | The reagent is provided in aqueous buffered solution containing protein stabilizer, and ≤0.09% sodium Azide (NaN3). |
Immunogen | Human IL-2-dependent T-cell line. |
Concentration | Please refer to the Certificate of Analysis for the lot-specific concentration. Typically 0,05 mg/ml. |
CD45RO, clone UCHL1 is a mAb intended for identification/enumeration of CD45RO present on approx. 40% of peripheral blood T lymph using FCM. This reagent is effective for direct IF staining of human tissue for FCM analysis using ≤1 μg/10^6 cells.
Product description | Reference | Title | Authors | Journal | Year | |
---|---|---|---|---|---|---|
Product description | Reference | Title | Authors | Journal | Year |
© 2023 Immunostep